Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301297 | 0.98 | MAPT (0.59) | MAPTALDH1A1HTTHPGDCYP1A2 | |
| SCHEMBL5236395 | 0.88 | HPGD (0.62) | MAPTALDH1A1HTTHPGDCYP1A2 | |
| SCHEMBL82777 | 0.86 | MAPT (0.60) | MAPTALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL1114152 | 0.86 | MAPT (0.60) | MAPTALDH1A1HTTHPGDCYP1A2 | |
| SCHEMBL16318379 | 0.82 | VCAM1 (0.50) | MAPTALDH1A1HTTCYP1A2CYP2C19 | |
| SCHEMBL16318378 | 0.82 | VCAM1 (0.50) | MAPTALDH1A1HTTCYP1A2CYP2C19 | |
| SCHEMBL10058378 | 0.81 | LMNA (0.46) | MAPTALDH1A1HTTCYP1A2CYP2C19 | |
| SCHEMBL25855470 | 0.81 | HPGD (0.73) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL12733348 | 0.80 | VCAM1 (0.45) | MAPTALDH1A1HTTHPGDCYP1A2 | |
| SCHEMBL27957502 | 0.78 | HPGD (0.64) | MAPTALDH1A1HPGDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | MAPT 4404/4885ALDH1A1 4380/4885HTT 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.